kidney cancer
With Positive Multi-Site Trial Data, Elypta Poised for Launch of Kidney Cancer Surveillance Test
Premium
The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.
Myriad Genetics, MD Anderson Partner to Study MRD Testing in Renal Cell Carcinoma
Researchers will explore whether Myriad's Precise MRD test can be used to inform treatment, monitor disease progression, and track treatment response.
ESHG: UK Study Finds 6 Percent of Renal Cell Carcinoma Patients Carry Cancer Risk Variant
Researchers looked for pathogenic or likely pathogenic variants in 121 cancer risk genes in whole-genome sequencing data from 1,336 unselected RCC patients.
Elypta Expands Trial for Liquid Biopsy Kidney Cancer Recurrence Test; Plans Bladder Cancer Assay
Premium
Elypta is also developing a third test for the early detection of multiple cancers, which the company believes could eventually be used for routine cancer screening.
Allarity Therapeutics Seeks FDA Premarket Approval for Prediction Tool as CDx for Dovitinib
The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.